What's the average survival increase with polivy for lymphoma patients?

Polivy (polatuzumab vedotin) can improve survival, but the amount depends on the lymphoma setting and regimen. Here are the main points from the major trials:

- Relapsed/refractory DLBCL (polatuzumab vedotin + bendamustine + rituximab vs bendamustine + rituximab)
- This regimen has shown a meaningful overall survival benefit in that setting. In the pivotal GO29365 trial, median overall survival was longer with pola-BR (roughly around 12 months) than with BR alone (roughly around 4–5 months), corresponding to several months of added survival.

- Newly diagnosed (frontline) DLBCL (polatuzumab vedotin + R-CHP vs R-CHOP)
- In the POLARIX trial, polatuzumab vedotin with CHP improved progression-free survival (PFS) versus standard R-CHOP. The improvement is in PFS, not yet clearly shown as an overall survival (OS) benefit at the time of the reported results.

Important caveats:
- The exact “average” survival increase varies by regimen and patient population.
- OS benefit is clearer in the relapsed/refractory setting with pola-BR; in the frontline setting, OS benefit has not been clearly demonstrated yet in published results.
- Always refer to the latest FDA label and trial publications for precise numbers and current approvals.

If you tell me which lymphoma type and whether you’re asking about relapsed/refractory or frontline disease, I can pull the exact figures from the relevant trial and the current labeling.